Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects
A Phase 1, Randomized, Double Blind (Sponsor Open), Placebo Controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06260414 In Healthy Western And Japanese Male Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06511
- New Haven Clinical Research Unit
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male between the ages of 21 and 50 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG and clinical laboratory tests).
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
- Additional inclusion criteria for subjects to be enrolled in Japanese cohort only: Japanese subjects who have four Japanese grandparents born in Japan.
Exclusion Criteria:
- Serum total testosterone level <270 or >1070 ng/dL
- Serum Prostate Specific Antigen (PSA) level >4 ng/mL.
- Hematocrit >48%.
- eGFR >150 ml/min/1.73m2.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: SAD cohorts 1-7 Experimental Arm
|
Subjects will receive single doses of 1,3,6,30,100,200, 400 mg of PF-06260414 (solution) in a dose escalating format
Subjects will receive PF-06260414 doses (solution) twice daily for 14 days
Japanese subjects may receive the highest dose of PF-06460414 tested in non Japanese cohort twice daily for 14 days
|
|
Placebo Comparator: SAD Cohorts 1-7 Placebo Arm
|
Subjects will receive single doses of PF-06260414 matching placebo (solution) in a dose escalation format
Subjects will receive PF-06260414 matching placebo doses (solution) of 3, 10, 30, 100mg BID and 60 mg QD for 14 days
Japanese subjects may receive PF-06260414 matching placebo doses (solution) twice daily for 14 days
|
|
Experimental: MAD cohorts 2-6 Experimental Arm
|
Subjects will receive single doses of 1,3,6,30,100,200, 400 mg of PF-06260414 (solution) in a dose escalating format
Subjects will receive PF-06260414 doses (solution) twice daily for 14 days
Japanese subjects may receive the highest dose of PF-06460414 tested in non Japanese cohort twice daily for 14 days
|
|
Placebo Comparator: MAD cohorts 2-6 Placebo Arm
|
Subjects will receive single doses of PF-06260414 matching placebo (solution) in a dose escalation format
Subjects will receive PF-06260414 matching placebo doses (solution) of 3, 10, 30, 100mg BID and 60 mg QD for 14 days
Japanese subjects may receive PF-06260414 matching placebo doses (solution) twice daily for 14 days
|
|
Experimental: Japanese MAD cohort 7 Experimental arm
|
Subjects will receive single doses of 1,3,6,30,100,200, 400 mg of PF-06260414 (solution) in a dose escalating format
Subjects will receive PF-06260414 doses (solution) twice daily for 14 days
Japanese subjects may receive the highest dose of PF-06460414 tested in non Japanese cohort twice daily for 14 days
|
|
Placebo Comparator: Japanese MAD cohort 7 Placebo Arm
|
Subjects will receive single doses of PF-06260414 matching placebo (solution) in a dose escalation format
Subjects will receive PF-06260414 matching placebo doses (solution) of 3, 10, 30, 100mg BID and 60 mg QD for 14 days
Japanese subjects may receive PF-06260414 matching placebo doses (solution) twice daily for 14 days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes from baseline vital signs (blood pressure, pulse rate, oral temperature and respiration rate)
Time Frame: 6 weeks
|
6 weeks
|
|
|
Changes from baseline in 12-lead ECG parameters
Time Frame: 6 weeks
|
Quantitative changes in ECG intervals
|
6 weeks
|
|
Incidence and severity of treatment emergent adverse events and withdrawals due to treatment emergent adverse events
Time Frame: 6 weeks
|
6 weeks
|
|
|
Incidence and magnitude of treatment emergent clinical laboratory abnormalities including hematology (including total Hb and hematocrit), chemistry, fasting glucose, urinalysis
Time Frame: 6 weeks
|
6 weeks
|
|
|
24 hour creatinine clearance (baseline and day 14).
Time Frame: Baseline, Day 14
|
Baseline, Day 14
|
|
|
Changes from baseline in total testosterone, free testosterone, estradiol, LH, FSH, SHBG.
Time Frame: 6 weeks
|
6 weeks
|
|
|
Changes from baseline in Prostate Specific Antigen (PSA).
Time Frame: 6 weeks
|
6 weeks
|
|
|
Changes from baseline in total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides.
Time Frame: 6 weeks
|
6 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Single Dose: Cmax, Tmax, AUClast, AUCinf, CL/F, Vz/F, and t½,Cmax(dn), AUCinf(dn), AUClast(dn), t½.
Time Frame: 6 weeks
|
6 weeks
|
|
|
Multiple Dose: Cmax, Tmax Ctrough, C,av,AUC,CL/F, Vz/F, Rac , Rac,Cmax , PTR, Cmax(dn),AUCτ(dn), t½.
Time Frame: 6 weeks
|
6 weeks
|
|
|
Urinary Pharmacokinetics: Amount of PF 06260414 excreted unchanged (AE and AE%), renal clearance (CLr).
Time Frame: 6 weeks
|
6 weeks
|
|
|
Single Dose: AUC(hormone or PSA), C0(hormone or PSA), Maximum PCB, Cmax(hormone or PSA), Cmin(hormone or PSA), Tmax(hormone or PSA), Tmin(hormone or PSA).
Time Frame: 6 weeks
|
The effects of PF- 06260414 on sex hormones (total testosterone, free testosterone, estradiol, SHBG, LH and FSH) will be evaluated according to the scheduled timepoints in single ascending dose study
|
6 weeks
|
|
Multiple Dose: AUC(hormone or PSA), C0(hormone or PSA), Cmax(hormone or PSA), Cmin(hormone or PSA), Tmax(hormone or PSA), Tmin(hormone or PSA).
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- B7411001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.